Governance & Derivative

Summit Therapeutics Inc. (NasdaqGM: SMMT)

Contact a Lawyer Now

(833) 938-0905

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Summit Therapeutics Inc. (“Summit”) (NasdaqGM: SMMT).

In April 2025, Summit removed the performance conditions applicable to stock options held by two of its senior executives, including its Co-CEO and President, Dr. Mahkam Zanganeh, the spouse of Summit’s controlling stockholder. Summit reported that the removal of the performance conditions increased the value of Zanganeh’s stock options by $245 million. KSF is investigating the fairness of the removal of the performance conditions, including whether Summit’s officers, directors or controlling stockholder breached their fiduciary duties in connection with the purchase.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Summit shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at (833) 938-0905 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or fill out the form on this page.